All News
Nailfold Capillaroscopy Portends Prognosis in Systemic Sclerosis
Two reports underscore the importance of nailfold capillaroscopy (NFC) in scleroderma and have shown that nailfold capillary drop out was significantly associated with mortality in systemic sclerosis.
Read ArticleThe RheumNow Week in Review - 2 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes rising epidemiologic numbers, vaccine updates for H.
Read ArticleInefficacy of Immunosuppressive Treatments in Systemic Sclerosis with ILD
EUSTAR study results published in Arthritis Research & Therapy show the current state of immunosuppressive use in systemic sclerosis patients with interstitial lung disease (SSc-ILD) to be ill-defined, but that liberal use of glucocorticoids (GC) in SSc-ILD should be discouraged
Read ArticleThe RheumNow Week in Review - 5 January 2018
Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read ArticleStem Cell Transplant Succeeds in Scleroderma
Myeloablative autologous stem cell transplantation was significantly more effective than 12 months of cyclophosphamide among patients with severe scleroderma, an open-label multicenter study found.
Read ArticleCochrane Review: Calcium Channel Blocker Efficacy in Raynaud's
The Cochrane Database has published its review of calcium channel blockers (CCB) in Raynaud's phenomenon, showing CCBs may be useful in reducing the frequency, duration, severity of attacks, pain and disability associated with Raynaud's phenomenon, especially with primary Raynaud's.
Read ArticleFatigue, HAQ and Hand Disability Correlated in Early Systemic Sclerosis
Early diffuse cutaneous systemic sclerosis (SSc) was associated with high levels of disability and fatigue, according to analysis of data from the European Scleroderma Observational Study cohort.
Read ArticleThe ACR17 RheumNow Week in Review - 1 December 2017
Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.
Read ArticleKey Takeaways from ACR Review Course
The ACR Review Course was superb once again from top to bottom, from Blue Fingers to Practical Treatment of RA. Every year I wonder if I should skip it, but each year I go. And I have never regretted it. Here are my take-home messages and “pearls” from the ACR Review Course.
Read ArticleTocilizumab Benefits Persist in SSc
Clinically meaningful improvements in systemic sclerosis among patients treated with subcutaneous tocilizumab (Actemra) persisted during the open-label phase of a multinational randomized phase II trial, researchers reported.
Read Article13 October 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!
Read Article15 September 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, vaccination, and the repeated wonders of Vitamin D.
Read ArticleThe RheumNow Week in Review – 11 August 2017
The RheumNow Week in Review caps the week's news every Friday. Dr Jack Cush reviews the news, journal reports and important events from the past week in rheumatology.
Read ArticleThe RheumNow Week in Review – 4 August 2017
Dr. Jack Cush reviews new FDA decisions on sirukumab and tofacitinib as well as other news items from the past week on RheumNow.com.
Read ArticleNo Increase in Malformations with Etanercept Use During Pregnancy
While there are several reports detailing uncontrolled, observational results of biologic use during pregnancy, most are hampered by low numbers, incomplete data and too small a sample to make reliable judgements regarding the teratogenicity. A company sponsored claims data analysis has shown that etanercept exposure during pregnancy was not associated with an increase in major congenital malformations (MCMs).
Read ArticleTubulointerstitial Damage in Lupus Predicts ESRD Progression
The presence of tubulointerstitial damage (TID) may provide a potential window for early intervention in lupus nephritis (LN) to ward off end-stage renal disease (ESRD), according to a data analysis.
Read ArticleThe RheumNow Week in Review – 12 May 2017
Dr. Jack Cush highlights the big stories, news and articles from this week at RheumNow.com.
Read ArticleThe RheumNow Week in Review – 24 February 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Read ArticleImmunosuppressives Fail to Benefit Early Skin Scleroderma
Treatment of systemic sclerosis is difficult, as there have few proven therapies capable of altering the course of the disease. Ideally, early intervention affords the optimal scenario wherein drug intervention can be proven to work.
Read ArticleFDA Issues Draft Guidance on Biosimilar Interchangeability
Interchangeability, or the substitution of a biosimilar for its innovator biologic, is on the horizon. Will the prescriber chose the biosimilar in place of the originator? Or will this allow pharmacists or healthcare plans to substitute a biosimilar, without intervention from a healthcare provider?
Read Article